

## Consolidated Income Statement

	2008 Q4	2007 Q4	2008 YTD	2007 YTD
Sales .....	150.501	78.869	540.149	289.817
Cost of sales .....	(107.617)	(53.692)	(361.218)	(192.581)
<b>Gross profit</b>	<u>42.884</u>	<u>25.177</u>	<u>178.931</u>	<u>97.236</u>
Other operating income .....	(189)	(66)	716	1.203
Selling and marketing expenses .....	(20.587)	(12.172)	(71.838)	(44.829)
Research and development expenses .....	(7.644)	(4.237)	(27.337)	(14.631)
Administrative expenses .....	(21.883)	(7.100)	(60.038)	(28.950)
<b>Profit from operations</b>	<u>(7.419)</u>	<u>1.602</u>	<u>20.434</u>	<u>10.029</u>
Finance costs - net .....	(22.387)	(2.277)	(32.194)	(7.091)
Share of results of associates .....	0	5.125	473	4.602
<b>Profit before income tax</b>	<u>(29.806)</u>	<u>4.450</u>	<u>(11.287)</u>	<u>7.540</u>
Income tax expense .....	6.076	(1.077)	2.882	(1.474)
<b>Net profit</b>	<u>(23.730)</u>	<u>3.373</u>	<u>(8.405)</u>	<u>6.066</u>
<b>Attributable to:</b>				
Equity holders of the Company .....	(23.730)	3.367	(8.405)	6.065
Minority interest .....	0	6	0	1
	<u>(23.730)</u>	<u>3.373</u>	<u>(8.405)</u>	<u>6.066</u>

# Consolidated Balance Sheet

	31/12 2008	31/12 2007
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment .....	145.420	66.305
Goodwill and other intangible assets .....	482.688	120.035
Investments in associates .....	305	3.281
Deferred income tax assets .....	5.620	3.542
Available-for-sale investments .....	28	631
Receivables .....	2.684	245
Derivative financial instruments .....	0	127
	<u>636.745</u>	<u>194.166</u>
<b>Current assets</b>		
Inventories .....	113.637	61.587
Production contracts .....	26.473	15.168
Trade receivables .....	85.629	52.871
Other receivables and prepayments .....	34.652	20.427
Loan to Associate .....	0	49.607
Derivative financial instruments .....	4.364	3.041
Cash and cash equivalents .....	22.213	30.437
	<u>286.967</u>	<u>233.138</u>
<b>Total assets</b>	<u><u>923.712</u></u>	<u><u>427.304</u></u>
<b>EQUITY</b>		
<b>Capital and reserves attributable to equity holders of the Company</b>		
Ordinary shares .....	5.868	4.452
Treasury shares .....	(16)	(38)
Share premium .....	269.988	147.584
Fair value and other reserves .....	(7.477)	(502)
Retained earnings .....	18.462	30.293
	<u>286.825</u>	<u>181.789</u>
<b>Minority interest</b>	0	46
<b>Total equity</b>	<u><u>286.825</u></u>	<u><u>181.835</u></u>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Borrowings .....	287.163	115.327
Deferred income tax liabilities .....	10.362	6.380
Provision .....	8.563	11
Derivative financial instruments .....	35.542	500
	<u>341.630</u>	<u>122.218</u>
<b>Current liabilities</b>		
Trade and other payables .....	161.110	75.487
Derivative financial instruments .....	8.260	117
Current income tax liabilities .....	6.703	736
Borrowings .....	113.281	45.029
Provisions .....	5.902	1.882
	<u>295.257</u>	<u>123.251</u>
<b>Total liabilities</b>	636.886	245.469
<b>Total equity and liabilities</b>	<u><u>923.712</u></u>	<u><u>427.304</u></u>

# Consolidated Cash Flow Statement

	2008	2007
<b>Cash flows from operating activities</b>		
Net profit .....	(8.405)	6.066
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and impairment of fixed assets .....	11.999	5.069
Amortisation and impairment of intangible assets .....	9.674	5.882
Currency fluctuations and indexation .....	(3.546)	260
Changes in deferred taxes .....	(4.210)	246
Share of results of associates .....	(244)	(4.602)
Other changes .....	(230)	66
Working capital provided by operating activities	<u>5.038</u>	<u>12.987</u>
Changes in operating assets and liabilities:		
Inventories and production contracts (decrease) .....	(1.118)	(12.115)
Trade and other receivables (decrease) .....	16.159	(20.399)
Short-term liabilities, increase .....	(6.416)	22.305
Changes in operating assets and liabilities	<u>8.625</u>	<u>(10.209)</u>
<b>Net cash from operating activities</b>	<b>13.663</b>	<b>2.778</b>
<b>Cash flows from investing activities</b>		
Acquisition of subsidiary, net of cash acquired .....	(423.170)	0
Purchase of property, plant and equipment (PPE) .....	(18.638)	(17.328)
Proceeds from sale of PPE .....	2.846	1.242
Purchase of intangible assets .....	(20.224)	(13.266)
Proceeds from sale of intangible assets .....	93	0
Purchase of associate investments .....	(1.061)	0
Loans made .....	0	(41.643)
Loan repayments received from associates .....	49.607	0
Proceeds from sale of equities .....	2.676	746
Net cash used in investing activities	<u>(407.871)</u>	<u>(70.249)</u>
<b>Cash flows from financing activities</b>		
Proceeds from issuance of ordinary shares .....	123.842	34.638
Proceeds from (purchase of) treasury shares, net .....		(2.154)
Proceeds from borrowings .....	285.434	24.669
Repayments of borrowings .....	(22.404)	(13.434)
Finance lease principal payments .....	(558)	(865)
Changes in short-term bank loans .....	166	(7.912)
Dividend paid to company's shareholders .....		(824)
Net cash from financing activities	<u>386.480</u>	<u>34.118</u>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(7.728)</b>	<b>(33.353)</b>
Exchange losses on cash and bank overdrafts .....	(496)	711
Cash and cash equivalents at beginning of year .....	30.437	63.079
<b>Cash and cash equivalents at end of year</b>	<b><u>22.213</u></b>	<b><u>30.437</u></b>